Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

Sakata, Koji; Hayakawa, Manabu; Yano, Yuichiro; Tamaki, Noboru; Yokota, Naoto; Eto, Takuma; Watanabe, Reiko; Hirayama, Naoteru; Matsuo, Takeshi; Kuroki, Kazuo; Sagara, Seiji; Mishima, Osamu; Koga, Masahiro; Nagata, Naoto; Nishino, Yoshinori; Kïtamura, Kazuo; Kario, Kazuomi; Takeuchi, Masayoshi; Yamagishi, Sho‐ichi

doi:10.1002/dmrr.2437

Cited by 64 publications

(54 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another clinical study (Hattori 2011) revealed that 6 months of sitagliptin treatment lowered systolic and diastolic blood pressure, blood glucose, C-reactive protein, soluble vascular cell adhesion molecule 1 and UACR in patients with type 2 diabetes. In agreement with these findings, Sakata and coworkers (Sakata et al 2013) demonstrated that fasting blood glucose, HbAlc, circulating soluble form of RAGE and UACR were decreased after treatment with alogliptin for twelve weeks in Japanese patients with type 2 diabetes. In addition, type 2 diabetic patients, treated with saxagliptin and followed for a median of 2.1 years, were significantly more likely than patients treated with placebo, to have a lower UACR (Scirica et al 2013).…”

Section: Clinical Data On Dpp-4 Inhibitors In Diabetic Nephropathysupporting

confidence: 55%

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

Hasan

Hocher

2017

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes. The available therapeutic approaches are limited. Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of glucose-lowering drugs that might also have reno-protective properties. DPP-4 exists in two forms: a plasma membranebound form and a soluble form, and can exert many biological actions mainly through its peptidase activity and interaction with extracellular matrix components. The kidneys have the highest DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are up-regulated in diabetic nephropathy, highlighting its role as a potential target to manage diabetic nephropathy. Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure-and glucose-independent manner. Many studies reported that these reno-protective effects could be due to increased half-life of DPP-4 substrates such as glucagon-like peptide-1 (GLP-1) and stromal derived factor-1 alpha (SDF-1a). However, the underlying mechanisms are far from being completely understood and clearly need further investigations.

show abstract

Section: Clinical Data On Dpp-4 Inhibitors In Diabetic Nephropathysupporting

confidence: 55%

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

Hasan

Hocher

2017

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…In type 2 diabetic subjects, administration of the dipeptidyl peptidase-4 (DPP4) inhibitor alogliptin resulted in reduced fasting glucose and reduced levels of sRAGE in parallel with reduced urinary albumin to creatinine ratio [56]. …”

Section: Modulation Of Soluble Rages: Studies In Vivomentioning

confidence: 99%

Soluble RAGEs — Prospects for treating & tracking metabolic and inflammatory disease

Schmidt

2015

Vascular Pharmacology

View full text Add to dashboard Cite

Emerging evidence links the receptor for advanced glycation endproducts (RAGE) to the pathogenesis of tissue damage in chronic metabolic and inflammatory diseases. In human subjects, multiple reports suggest that in the plasma/serum, circulating levels of distinct forms of soluble RAGEs may be biomarkers of the presence or absence, and the extent of chronic disease. These considerations prompt us to consider in this review, what are soluble RAGEs; how are they formed; what might be their natural functions; and may they serve as biomarkers of inflammatory and metabolic disease activity? In this brief review, we seek to address what is known and suggest new areas for scientific investigation to uncover the biology of soluble RAGEs.

show abstract

“…Moreover, atrovastatin, pioglitazone and α-glucosidase inhibitor have been shown to significantly decrease serum levels of glyceraldehyde-derived AGEs, which are associated with reduced biomarker levels for organ damage in diabetic, chronic kidney disease or NASH subjects (120,(124)(125)(126)(127)(128).…”

Section: Measuring Serum Levels Of Ages and Its Clinical Utilitymentioning

confidence: 99%

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Yamagishi

Nakamura

Suematsu

et al. 2015

Mol Med

Self Cite

144

View full text Add to dashboard Cite

Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

Abstract: Alogliptin treatment improved the AGE-RAGE axis and reduced albuminuria in Japanese type 2 diabetes patients.

Cited by 64 publications

References 34 publications

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

Soluble RAGEs — Prospects for treating & tracking metabolic and inflammatory disease

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Contact Info

Product

Resources

About